| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | silmitasertib | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | -0.0082 | 0.9 |